Japanese medical technology company Olympus and Revival Healthcare Capital have partnered to launch Swan EndoSurgical, a new venture for advancing endoluminal gastrointestinal robotics.
The strategic partnership aims to develop advanced robotic systems to enhance gastrointestinal (GI) patient care through safe and effective minimally invasive treatment.
Swan EndoSurgical will focus on developing a novel robotic system designed to improve precision and efficiency in GI procedures.
By empowering physicians to perform advanced techniques, the technology aims to enhance patient access to innovative treatments and reduce recovery times.
The initiative addresses significant unmet medical needs in the field of GI healthcare.
Olympus representative executive officer, president and CEO Bob White said: “This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics.
“We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians.
“This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.”
Endoluminal robotics represents a major advancement in medical technology, allowing for the manoeuvrability of flexible arms within the GI tract.
The advancement could enable more patients to benefit from procedures that currently require invasive surgery, facilitating early and effective treatment of lesions or tumours.
Traditionally, endoscopy has relied on manual endoscopes, which have limitations in performing advanced procedures within the GI tract.
The constraints often make such treatments challenging and less accessible globally, underscoring the importance of Swan EndoSurgical’s innovative approach.
Based in the US, Swan EndoSurgical will be led by a team of experienced professionals.
The leadership will drive the technical, clinical, and commercial development of the robotic platform, aiming to redefine current therapeutic options in the GI sector.
